LAUSR

During the coronavirus disease (COVID-19) pandemic, the number of patients eligible to receive extracorporeal membrane oxygenation (ECMO) has exceeded the availability of this resource-intensive therapy (1). To maximize benefit, many centers have incorporated survival predictions into allocation processes (2). However, existing tools to predict mortality among patients receiving ECMOwere generated from patient cohorts with non–COVID-19–related acute respiratory distress syndrome (3, 4) and may perform poorly when applied to patient cohorts with COVID-19 (5). Whether a tool created from a cohort of patients with COVID-19 would demonstrate improved performance is unknown.We derived and validated a simple bedside tool for predicting hospital mortality for patients with COVID-19 being considered for ECMO and compared its performance to the performance of the Respiratory ECMO Survival Prediction (RESP) score, a commonly used prognostic model for survival during ECMO developed before the COVID-19 pandemic (3).